Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by serendipidyon Jun 26, 2018 1:46pm

103 Views

Post# 28231295

RE:RE:RE:RE:RE:RE:RE:Penny Flippers

do you read? Gwpharma was set for the news release on the 27th, ( if came out early) when I spoke with I.r. they said to call back after the 28th as things will be more transparent. So from that one, who is educated, would assume that there is something tied to gwpharma getting FDA approval ie. - FINANCING, as that is the only piece of the puzzle we are missing now.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale